Adipose Tissue-Derived Mesenchymal Stem Cells Induce Expansion of Interleukin-10-Producing Regulatory B Cells and Ameliorate Autoimmunity in a Murine Model of Systemic Lupus Erythematosus

Adipose Tissue-Derived Mesenchymal Stem Cells Induce Expansion of Interleukin-10-Producing Regulatory B Cells and Ameliorate Autoimmunity in a Murine Model of Systemic Lupus Erythematosus

Blog Article

Mesenchymal stem cells (MSCs) are multipotent Special Tags cells characterized by immunomodulatory properties and are therefore considered a promising tool for the treatment of autoimmune diseases.One functional B-cell subset, regulatory B cells (Bregs), has recently been shown to restrain excessive inflammatory responses in autoimmune diseases.In the present study, we investigated the impact of human adipose-derived MSCs on Bregs and their therapeutic effect in an animal model of systemic lupus erythematosus (SLE).Coculture of human adipose-derived MSCs with splenocytes from C57BL/6 mice expanded the population of interleukin-10-producing B cells (B10 B cells).In vivo treatment with human adipose-derived MSCs reduced serum anti-double-stranded antibody levels and improved renal pathology of lupus mice (Roquin san/san mice).

MSCs decreased ICOS + CD44 + follicular helper T cells, Th1 cells and Th17 cells, in spleens of Roquin san/san mice.In contrast, MSCs increased Foxp3-expressing regulatory T cells.MSCs also decreased the size and number of germinal centers and effector B cells.As expected, in vivo treatment with MSCs expanded the population of Bregs in spleens of Roquin san/san mice.Our results indicate that human adipose-derived MSCs Mouthguard induce the expansion of Bregs and ameliorate autoimmunity in a murine model of SLE.

These findings suggest that human adipose-derived MSCs may be a promising therapeutic strategy targeting B-cell-mediated autoimmune diseases such as SLE.